Health Care Technology
Company Overview of Celmatix Inc.
Celmatix Inc. operates as a personalized medicine company that focuses on women’s health. It uses predictive analytics and genomics to create products that help in infertility treatment and proactive fertility management. The company offers POLARIS, a Web-based analytics platform for optimizing a woman’s fertility by calculating personal likelihood of success using various fertility treatment options, tailored to a patient’s clinical metrics; and NOVA, a patient portal that helps clinics to maximize the patient experience. Its products help women to make informed decisions about their fertility, as well as provide doctors with data-driven tools for patient care. Celmatix Inc. was founded in ...
14 Wall Street
New York, NY 10005
Founded in 2009
Key Executives for Celmatix Inc.
Founder, Chief Executive Officer and Director
Compensation as of Fiscal Year 2016.
Celmatix Inc. Key Developments
Celmatix Appoints Mark Adams as Chief Information Officer
Sep 1 16
Celmatix announced that it has named Mark Adams, PhD, as its first Chief Information Officer. In this position, Dr. Adams will play a critical role on the leadership team, scaling the company’s bioinformatics and data analytics operations to support both the upcoming commercial launch of its genetic test and ongoing growth of the company's SaaS platform, Polaris. Dr. Adams is a pioneer in the genomics space, having led some of the earliest commercial bioinformatics efforts to explore and use genomic data and information while at companies such as Variagenics and Incyte. While at Variagenics, he worked to build the company’s first informatics pipeline, supporting high-throughput SNP genomics. He joins Celmatix from Good Start Genetics where he served as Chief Information Officer.
Celmatix Names Erin Foran Wolff as its Chief Medical Officer
May 18 16
Celmatix announced that it has named Dr. Erin Foran Wolff as its first Chief Medical Officer. In this position, Dr. Wolff will play an important role as the company prepares to launch its first genetic test and continues to scale its analytics platform, Polaris, already in use at leading fertility clinics across the US. In addition, Dr. Wolff will help support the ongoing clinical research efforts of the company. Dr. Wolff comes to Celmatix from the National Institutes of Health in Washington, D.C., where she conducted basic, translational, and clinical reproductive research as an Assistant Clinical Investigator for the past five years.
Celmatix Appoints Ardy Arianpour to its Corporate Advisory Board
Feb 18 16
Celmatix announced the appointment of Ardy Arianpour to its Corporate Advisory Board. Arianpour was most recently the Chief Commercial Officer of Pathway Genomics, after holding senior executive roles at a number of leading personalized medicine companies including Ambry Genetics and Cogenics.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 18, 2016
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries